Keravive by Hydrafacial for Scalp Health and Enhanced Hair Quality

Completed · Not applicable

Conditions studied: Androgenic Alopecia

In brief

The study aims to assess the efficacy and safety of Keravive by Hydrafacial treatments and Keravive Peptide Spray for scalp health and enhancing hair quality in patients with androgenic alopecia. This study is intended to be a single arm study. Suitable subjects who meet all inclusion criteria and consented will undergo 3 in-office Keravive by Hydrafacial treatments at Day 0 and Weeks 4 and 8 in combination with daily application on Keravive Peptide Spray at home. Subjects will be assessed at Day 0, and Weeks 4, 8, and 20 by investigators using the Norwood Scale (males), Ludwig Classification (females), and a series of Likert scales for ranking improvement in scalp health and hair quality.

Key facts

Study ID

NCT06112782

Run by

Beauty Health

People needed

44

Starts

2019-07-01

Expected to finish

2020-01-31

Last updated by the study team

2023-11-01

Who can join

Age: 30 and older, up to 55. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Norwood Scale score of 2, 3 or 3 Vertex (males) and Ludwig Classification of Type I-1, I-2 or I-3 (females).

You may not qualify if…

• Non-study hair loss treatments (e.g., dutasteride, finasteride, minoxidil, nutraceuticals, PRP therapy, laser or LED scalp treatments, etc.)
• Salon treatments such as straightening, perms or coloring.

Where it is running

• Rebecca Fitzgerald MD Inc — Los Angeles, California, United States
• Laser & Skin Surgery Medical Group, Inc — Sacramento, California, United States
• ATS Clinical Research — Santa Monica, California, United States
• Callender Center for Clinical Research — Glenn Dale, Maryland, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.